XML 45 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenue (Tables)
 12 Months Ended
Dec. 31, 2018
Risks and Uncertainties [Abstract]  
Disaggregation of Revenue
The following table and description below shows the products from which the Company generated its revenue:
 
 
Year Ended December 31,
Revenue by product (in thousands)
 
2018
 
2017
 
2016
MACI and Carticel implants and kits
 
 
 
 
 
 
Implants - based on contracted rate
 
$
40,830

 
$
30,366

 
$
17,027

Implants - based on third party reimbursement
 
25,096

 
12,122

 
20,299

Biopsy kits - direct bill
 
1,997

 
1,764

 
1,545

Change in estimates related to prior periods
 
(182
)
 
(350
)
 
—

Epicel
 
 
 
 
 
 
     Direct bill (hospital)
 
23,116

 
18,858

 
15,512

License Revenue
 
—

 
1,164

 
—

Total revenue
 
$
90,857

 
$
63,924

 
$
54,383
Schedules of concentration of risk
The Company's total revenue and accounts receivable balances were comprised of the following concentrations from its largest customers of Carticel, MACI and Epicel, as follows:

 
Revenue Concentration
 
Accounts Receivable Concentration
 
Year Ended December 31,
 
December 31,
 
2018
 
2017
 
2016
 
2018
 
2017
Carticel and MACI
16
%
 
35
%
 
31
%
 
2
%
 
46
%
Epicel
7
%
 
10
%
 
11
%
 
4
%
 
3
%